Thanh bên bài viết

PDF
Ngày xuất bản: 29/04/2025
Số lượt xem tóm tắt: 138
Số lượt xem PDF: 44
DOI: https://doi.org/10.51298/vmj.v550i1.13879
Số xuất bản
Tập 550 Số 1 (2025): Vietnam Medical Journal
Chuyên mục
Các bài báo
Trích dẫn bài báo
Hua , M. Q., Nguyen , T. T. T., Pham , T. B. T., Lac , T. K. N., Truong , D. H., Dang , H. C., Nguyen , T. H., Le , V. D., Do , H. L., Huynh , V. B., Tran , D. H., & Tran , G. H. (2025). ASSESSMENT OF SLEEP DISORDERS BEFORE AND AFTER ITRACONAZOLE TREATMENT IN SEBORRHEIC DERMATITIS. Tạp Chí Y học Việt Nam, 550(1). https://doi.org/10.51298/vmj.v550i1.13879

ASSESSMENT OF SLEEP DISORDERS BEFORE AND AFTER ITRACONAZOLE TREATMENT IN SEBORRHEIC DERMATITIS

Hua My Quyen1, Nguyen Thi Thuy Trang2, Pham Thi Bao Tram2, Lac Thi Kim Ngan2, Truong Dieu Hien3, Dang Hoang Chuong3, Nguyen Trung Hau3, Le Van Dat3, Do Hoang Long4, Huynh Van Ba2, Tran Do Hung5, Tran Gia Hung2,
1 Residency Program in Dermatology, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam
2 Department of Dermato-Venereology, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam
3 Can Tho Hospital of Dermatology, Can Tho City, Vietnam
4 Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam
5 Faculty of Nursing and Medical Technology, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam

Nội dung chính của bài viết

Tóm tắt

Objectives: To assess the prevalence of sleep disorders before and after itraconazole treatment in patients with seborrheic dermatitis. Research object and Method: This cross-sectional study included 45 patients diagnosed with seborrheic dermatitis who sought treatment at Can Tho Dermatology Hospital between June 2024 and November 2024. Sleep disturbances were evaluated using the Pittsburgh Sleep Quality Index (PSQI) before and after treatment. The effectiveness of itraconazole was assessed based on symptom severity (erythema, scaling, itching, and burning), scored on a 0–3 scale (none–severe) over six weeks. Results: Before treatment, 28.9% of patients experienced sleep disorders, with prevalence rates of 21.6% in those with moderate SD and 62.5% in those with severe SD. Following itraconazole treatment, the prevalence of sleep disorders significantly decreased to 6.7% (p < 0.001). Treatment outcomes improved over time, with 51.1%, 84.5%, and 95.6% of patients achieving good or excellent results at weeks 2, 4, and 6, respectively. Patients with moderate SD showed better treatment responses compared to those with severe SD. No adverse effects related to itraconazole were reported during the six-week follow-up. Conclusion: Sleep disturbances in seborrheic dermatitis were correlated with disease severity. After itraconazole treatment, patients experienced significant improvements in sleep quality, as indicated by lower PSQI scores. Patients with moderate SD responded more favorably to treatment than those with severe SD. These findings suggest that itraconazole is a safe and effective treatment option for managing both moderate and severe seborrheic dermatitis while also improving sleep quality.

Chi tiết bài viết

Từ khóa

seborrheic dermatitis, sleep disorders, itraconazole.

Tài liệu tham khảo

1. Tao R, Li R, Wang R. Skin microbiome alterations in seborrheic dermatitis and dandruff: A systematic review. Exp Dermatol. 2021 Oct;30(10):1546–53.
2. Tucker D, Masood S. Seborrheic Dermatitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Feb 26]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK551707/
3. Tamschick R, Navarini A, Strobel W, Müller S. Insomnia and other sleep disorders in dermatology patients: A questionnaire-based study with 634 patients. Clinics in Dermatology. 2021 Nov;39(6):996–1004.
4. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193–213.
5. Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: a comprehensive review. J Dermatolog Treat. 2019 Mar;30(2):158–69.
6. Ghodsi SZ, Abbas Z, Abedeni R. Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Moderate to Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled Trial. Am J Clin Dermatol. 2015 Oct;16(5):431–7.
7. Van TN, Thi NH, Van TH, Van HL, Huu ND, Minh PPT, et al. Efficacy of Oral Itraconazole in the Treatment of Seborrheic Dermatitis in Vietnamese Adults Patients. Open Access Maced J Med Sci. 2019 Jan 30;7(2):224–6.
8. Shemer A, Kaplan B, Nathansohn N, Grunwald MH, Amichai B, Trau H. Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non-comparative study. Isr Med Assoc J. 2008 Jun;10(6):417–8.
10. Chau HH, Huynh VB. The Effects of Treatment for Adult Seborrheic Dermatitis by Using The Combination of Itraconazole and E-Psora at Can Tho Dermato-Venereology Hospital in 2021-2022. ctump. 2023 Feb 28;(57):74–9.
11. Hien DTT, Trung LV, Anh NTH. Clinical and Subclinical Characteristics of Patients with Moderate and Severe Seborrheic Dermatitis. YHCĐ [Internet]. 2024 Jun 10 [cited 2025 Feb 27];65(4). Available from: https://tapchiyhcd.vn/index.php/yhcd/article/view/1193
12. Bukvić Mokos Z, Kralj M, Basta-Juzbašić A, Lakoš Jukić I. Seborrheic dermatitis: an update. Acta Dermatovenerol Croat. 2012;20(2):98–104.
13. Halioua B, Misery L, Seite S, Delvigne V, Chelli C, Taieb J, et al. Influence of Skin Subjective Symptoms on Sleep Quality in Patients with Cutaneous Disorders: A Study of 2871 Subjects. Clin Cosmet Investig Dermatol. 2021;14:143–52.
14. Zeidler C, Kupfer J, Dalgard FJ, Bewley A, Evers AWM, Gieler U, et al. Dermatological patients with itch report more stress, stigmatization experience, anxiety and depression compared to patients without itch: Results from a European multi-centre study. J Eur Acad Dermatol Venereol. 2024 Aug;38(8):1649–61.
15. Das J, Majumdar M, Chakraborty U, Majumdar V, Mazumdar G, Nath J. Oral itraconazole for the treatment of severe seborrhoeic dermatitis. Indian J Dermatol. 2011;56(5):515–6.